BIIB Stock Jumps 5% — Analysts Raise Price Targets After FDA Clears Alzheimer’s Treatment For At-Home Use

Biogen's lecanemab received a public reimbursement recommendation in Canada, with pCPA talks and provincial decisions next. HSBC raised its price target to $175, citing disciplined capital use and a strong pipeline. Traders highlight expansion into nephrology and immunology, and the rollout of felzartamab and SYFOVRE.

Stoke Therapeutics and Biogen reported long-term data from trials of zorevunersen, an experimental treatment for Dravet syndrome. The therapy showed reductions in seizure rates, improved communication, and quality of life, with a good safety profile. Phase 3 trial results are expected next year, which will support a U.S. approval application.

Eisai and Biogen announced that China approved LEQEMBI SC-AI for early Alzheimer's treatment. Launch is planned by March 2027. Eisai estimates 17M potential patients in China. LEQEMBI targets both protofibrils and amyloid plaque, slowing disease progression by 27% in trials. Eisai leads global development, with co-commercialization by both companies.

Eisai and Biogen announced that China's NMPA approved LEQEMBI (lecanemab) subcutaneous formulation for early Alzheimer's disease. The self-administered autoinjector offers at-home treatment, reducing clinic visits. Eisai plans to launch it by March 2027. LEQEMBI targets amyloid protofibrils and plaques, slowing disease progression. Eisai leads global development, with both companies co-commercializing.

Eisai and Biogen announced that Canada’s Drug Agency recommended public reimbursement for LEQEMBI, a treatment for early Alzheimer’s disease. The decision follows a reconsideration and is a step toward broader access in Canada. Eisai leads development, while both companies co-commercialize the product. Over 770,000 Canadians live with dementia, a number projected to rise to 1.7 million by 2050.

Canada's Drug Agency recommended public reimbursement for Eisai and Biogen's LEQEMBI (lecanemab) for early Alzheimer's. The next step is negotiations with the pan-Canadian Pharmaceutical Alliance. Eisai leads development, with both companies co-commercializing.